| Ytd | -99.12% | |
| 1y | -99.62% |
| Open | 3.06 | Prev Close | 3.92 | Low | 2.80 | High | 4.65 | Mkt Cap | 3.04M |
| Vol | 13.59M | Avg Vol | 113.58K | EPS | 77.26 | P/E | 0.06 | Forward P/E | -11.83 |
| Beta | 1.35 | Short Ratio | 0.22 | Inst. Own | 1.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.39 | 200-d Avg | 9.00 | 1yr Est | 0.00 |
RSLS News
“From 2019 to 2025, the biomarker landscape has seen a surge in strategic collaborations, licensing,
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage he
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare c
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company tar
IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal;
Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Co
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asse
Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and
IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the prem
Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progr
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Vagal Neu
Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full P
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company
IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier
IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premi
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 700 points on Mo
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premi
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for tra
Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstra
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable I
